Deluge of Leveraged Buyout Debt to Hit High-Yield Market


(Bloomberg) — A deluge of leveraged buyout debt has been building up for months and is finally set to hit the high-yield market next week.

Private equity firms are expected to begin selling bonds to help fund the leveraged buyout of Medline Industries Inc., the biggest buyout since the financial crisis. The sale will potentially include $4 billion of unsecured notes and $3.8 billion of secured bonds, on top of $7 billion of leveraged loans that banks have already started selling.

Medline, a health-care product firm, will hold a lender call for the leveraged loans, one of the largest offerings of the debt in the past decade, on Monday at 11 a.m. in New York, according to a person with knowledge of the matter.

Specialty chemical maker Solenis LLC is scheduled to price $2.4 billion of bonds split between dollar-and euro-denominated portions that will help finance its buyout by Platinum Equity. The U.S. dollar portion of the deal is being discussed with a yield of as much as 7%, according to people with knowledge of the matter. It’s also in the leveraged loan market with a $1.4 billion-equivalent cross-border sale.

DexKo Global Inc. will kick off investor outreach Monday for a $665 million high-yield note sale. Proceeds from the offering will fund the acquisition of the vehicle-parts supplier by a unit of Brookfield Asset Management Inc. The company is also offering leveraged loans as part of the financing.

SAVE THE DATE: Crescent Capital, Carlyle Group, KKR & Co and Pretium Partners will be joining reporters from Bloomberg News to discuss the risks and opportunities that lie ahead in the $1.2 trillion leveraged loan market. Click here to register for the virtual event, which will take place on Sept. 28 at 11:00 a.m. in New York.

At least six leveraged loan deals have meetings set for next week, with Medline by far the largest. Commitments are due for 32 loan deals, the most in any week since February.

Investors have been expecting a surge of acquisition financings this month. As much as $110 billion of U.S. high-yield bond and leveraged loan sales are predicted to hit the market in September, according to a recent poll of bankers by Bloomberg, which would make it one of the busiest months in years. A hunt for higher yields amid rock-bottom rates elsewhere is helping underpin demand for the risky debt.

In distressed debt, lenders to Yak Access LLC are organizing after the maker of mats for construction projects posted a steep drop in earnings and weak liquidity in the second quarter, according to people with knowledge of the situation.

Investment Grade

High-grade bond supply should moderate next week, with Wall Street calling for $20 billion to $25 billion of sales, according to an informal survey of debt underwriters. An extraordinary $115 billion has priced over the last two weeks. September supply will likely approach monthly forecasts of $140 billion next week.

“Credit markets have weathered the pickup in supply well, with spreads tighter so far in September,” Barclays Plc strategists led by Bradley Rogoff wrote in a report Friday. “Deals continue to be oversubscribed, and concessions have been minimal.”

Still, Barclays sees further gains for high-grade credit as tough to come by.

“With spreads still close to multi-year tights, we think that further tightening from current levels will be challenging and that spreads could drift slightly wider into year-end,” the strategists wrote.

More stories like this are available on bloomberg.com

Subscribe now to stay ahead with the most trusted business news source.

©2021 Bloomberg L.P.



Read More:Deluge of Leveraged Buyout Debt to Hit High-Yield Market

2021-09-18 20:00:01

Get real time updates directly on you device, subscribe now.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.